Sanofi (SNY -0.2%) has apparently suspended recruitment in its studies testing the use of malaria med hydroxychloroquine in COVID-19 patients.
https://seekingalpha.com/news/3578717-sanofi-halts-enrollment-in-studies-of-malaria-drug-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.